FDA
-
-
-
-
-
-
-
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments
-
-
-
-
-
-
-
Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

